BRPI0814821A2 - Composto, composição farmacêutica, e, processo para preparar um composto - Google Patents

Composto, composição farmacêutica, e, processo para preparar um composto

Info

Publication number: BRPI0814821A2
Authority: BR; Brazil
Prior art keywords: compound; prepare; pharmaceutical composition; pharmaceutical; composition
Prior art date: 2007-07-16

Application number

BRPI0814821-0A2A

Other languages

English (en)

Inventor

Bernard Christopher Barlaam

Richard Ducray

Jason Grant Kettle

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-16

Filing date

2008-07-14

Publication date

2015-02-03

2008-07-14 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2015-02-03 Publication of BRPI0814821A2 publication Critical patent/BRPI0814821A2/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

BRPI0814821-0A2A 2007-07-16 2008-07-14 Composto, composição farmacêutica, e, processo para preparar um composto BRPI0814821A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP07301236		2007-07-16
PCT/GB2008/050562 WO2009010789A2 (en)	2007-07-16	2008-07-14	Pyrimidine derivatives 934

Publications (1)

Publication Number	Publication Date
BRPI0814821A2 true BRPI0814821A2 (pt)	2015-02-03

Family

ID=40260140

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0814821-0A2A BRPI0814821A2 (pt)	2007-07-16	2008-07-14	Composto, composição farmacêutica, e, processo para preparar um composto

Country Status (18)

Country	Link
US (1)	US7718653B2 (pt)
EP (1)	EP2183242A2 (pt)
JP (1)	JP2010533700A (pt)
KR (1)	KR20100042272A (pt)
CN (1)	CN101796046A (pt)
AU (1)	AU2008277446A1 (pt)
BR (1)	BRPI0814821A2 (pt)
CA (1)	CA2693880A1 (pt)
CO (1)	CO6260075A2 (pt)
CR (1)	CR11220A (pt)
DO (1)	DOP2010000022A (pt)
EA (1)	EA201000101A1 (pt)
EC (1)	ECSP109958A (pt)
MX (1)	MX2010000658A (pt)
NI (1)	NI201000011A (pt)
SV (1)	SV2010003459A (pt)
WO (1)	WO2009010789A2 (pt)
ZA (1)	ZA201000107B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2571867B1 (en)	2010-05-21	2015-11-04	Noviga Research AB	Novel pyrimidine derivatives
KR20140006048A (ko)	2011-03-24	2014-01-15	케밀리아 에이비	신규한 피리미딘 유도체
JP6027095B2 (ja)	2011-04-22	2016-11-16	シグナルファーマシューティカルズ，エルエルシー	置換されたジアミノカルボキサミドおよびジアミノカルボニトリルピリミジン、その組成物、ならびに、それを用いた治療方法
JP5931178B2 (ja)	2011-05-03	2016-06-08	フェニックスコンタクトゲーエムベーハーウントコムパニーカーゲー	電磁誘導による非接触電力伝送のための構成
CN103222842B (zh)	2013-04-18	2015-09-09	安翰光电技术（武汉）有限公司	一种控制胶囊内窥镜在人体消化道运动的装置及方法
NZ715903A (en)	2014-01-30	2017-06-30	Signal Pharm Llc	Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
NZ732793A (en)	2014-12-16	2023-07-28	Signal Pharm Llc	Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
ES2882954T3 (es)	2014-12-16	2021-12-03	Signal Pharm Llc	Usos médicos que comprenden métodos para la medición de la inhibición de la quinasa c-Jun N-terminal en la piel
EP3250557A4 (en)	2015-01-29	2018-06-20	Signal Pharmaceuticals, LLC	Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
JP6805232B2 (ja)	2015-07-24	2020-12-23	セルジーンコーポレイション	（１ｒ，２ｒ，５ｒ）−５−アミノ−２−メチルシクロヘキサノール塩酸塩の合成方法及びそれに有用な中間体
CN106543089A (zh) *	2016-11-04	2017-03-29	山东铂源药业有限公司	一种达沙替尼中间体的合成方法
EP4163278A1 (en) *	2020-05-29	2023-04-12	Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd.	Pyrimidine compound as axl inhibitor
CN116178434A (zh) *	2021-11-26	2023-05-30	南京正大天晴制药有限公司	Axl激酶抑制剂的单对甲苯磺酸盐及其晶型
CN116178433A (zh) *	2021-11-26	2023-05-30	南京正大天晴制药有限公司	Axl激酶抑制剂的盐及其制备方法和用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUP0301117A3 (en) *	2000-02-17	2004-01-28	Amgen Inc Thousand Oaks	Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
AU2003208686A1 (en)	2002-03-05	2003-09-16	Astrazeneca Ab	Alkylammonium salts of omeprazole and esomeprazole
GB0305929D0 (en) *	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
NZ585188A (en) *	2003-08-15	2011-09-30	Novartis Ag	2,4-Pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
US7521457B2 (en)	2004-08-20	2009-04-21	Boehringer Ingelheim International Gmbh	Pyrimidines as PLK inhibitors
GB0419161D0 (en) *	2004-08-27	2004-09-29	Novartis Ag	Organic compounds
CA2600531A1 (en)	2005-03-16	2006-09-28	Targegen, Inc.	Pyrimidine compounds and methods of use
WO2006129100A1 (en) *	2005-06-03	2006-12-07	Glaxo Group Limited	Novel compounds
WO2007028445A1 (en) *	2005-07-15	2007-03-15	Glaxo Group Limited	6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives
AR054834A1 (es)	2005-07-15	2007-07-18	Glaxo Group Ltd	Derivados de 1,1-dioxido-2,3-dihidro-1,2-benzoisotiazol-6-il-1h-indazol-4-il-2,4 pirimidina diamina
EP1934200A1 (en)	2005-09-15	2008-06-25	Merck & Co., Inc.	Tyrosine kinase inhibitors
MY167260A (en) *	2005-11-01	2018-08-14	Targegen Inc	Bi-aryl meta-pyrimidine inhibitors of kinases
TW200736232A (en)	2006-01-26	2007-10-01	Astrazeneca Ab	Pyrimidine derivatives
WO2007085540A1 (en)	2006-01-27	2007-08-02	Glaxo Group Limited	1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives
TW200840581A (en) *	2007-02-28	2008-10-16	Astrazeneca Ab	Novel pyrimidine derivatives
WO2008118822A1 (en) *	2007-03-23	2008-10-02	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
JP2010525047A (ja)	2007-04-27	2010-07-22	アストラゼネカアクチボラグ	増殖状態の処置のためのＥｐｈＢ４キナーゼ阻害剤としてのＮ’−（フェニル）−Ｎ−（モルホリン−４−イル−ピリジン−２−イル）−ピリミジン−２，４−ジアミン誘導体

2008
- 2008-07-14 BR BRPI0814821-0A2A patent/BRPI0814821A2/pt not_active IP Right Cessation
- 2008-07-14 WO PCT/GB2008/050562 patent/WO2009010789A2/en active Application Filing
- 2008-07-14 KR KR1020107002514A patent/KR20100042272A/ko not_active Application Discontinuation
- 2008-07-14 EA EA201000101A patent/EA201000101A1/ru unknown
- 2008-07-14 EP EP08776197A patent/EP2183242A2/en not_active Withdrawn
- 2008-07-14 JP JP2010516595A patent/JP2010533700A/ja active Pending
- 2008-07-14 MX MX2010000658A patent/MX2010000658A/es active IP Right Grant
- 2008-07-14 CA CA2693880A patent/CA2693880A1/en not_active Abandoned
- 2008-07-14 AU AU2008277446A patent/AU2008277446A1/en not_active Abandoned
- 2008-07-14 CN CN200880105690A patent/CN101796046A/zh active Pending
- 2008-07-16 US US12/174,339 patent/US7718653B2/en not_active Expired - Fee Related
2010
- 2010-01-06 ZA ZA201000107A patent/ZA201000107B/xx unknown
- 2010-01-15 SV SV2010003459A patent/SV2010003459A/es not_active Application Discontinuation
- 2010-01-15 DO DO2010000022A patent/DOP2010000022A/es unknown
- 2010-01-15 CR CR11220A patent/CR11220A/es not_active Application Discontinuation
- 2010-01-15 NI NI201000011A patent/NI201000011A/es unknown
- 2010-02-11 EC EC2010009958A patent/ECSP109958A/es unknown
- 2010-02-16 CO CO10017544A patent/CO6260075A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
CR11220A (es)	2010-05-20
KR20100042272A (ko)	2010-04-23
EP2183242A2 (en)	2010-05-12
CO6260075A2 (es)	2011-03-22
US20090023719A1 (en)	2009-01-22
JP2010533700A (ja)	2010-10-28
ECSP109958A (es)	2010-03-31
ZA201000107B (en)	2010-09-29
CN101796046A (zh)	2010-08-04
CA2693880A1 (en)	2009-01-22
WO2009010789A2 (en)	2009-01-22
WO2009010789A3 (en)	2009-05-07
DOP2010000022A (es)	2010-02-15
US7718653B2 (en)	2010-05-18
EA201000101A1 (ru)	2010-08-30
MX2010000658A (es)	2010-03-26
NI201000011A (es)	2010-12-07
AU2008277446A1 (en)	2009-01-22
SV2010003459A (es)	2010-04-30

Similar Documents

Publication	Publication Date	Title
BRPI0814821A2 (pt)	2015-02-03	Composto, composição farmacêutica, e, processo para preparar um composto
BRPI0818533A2 (pt)	2017-06-06	composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0814980A2 (pt)	2015-02-03	Processo para produzir um composto, e, composto.
BRPI0905717A2 (pt)	2015-07-14	Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica
BRPI0814611A2 (pt)	2015-01-27	Composição, processo para preparar uma composição, e, uso de uma composição
BRPI0909691A8 (pt)	2018-01-02	composto, método para preparar um composto, e, composição farmacêutica
BRPI0821676A2 (pt)	2015-06-16	Composto, composição farmacêutica, e, processo para a preparação dos compostos.
BRPI0813307A2 (pt)	2014-12-23	Composição imunogênica, vacina, e, processo para fabricar a vacina
BR112013008008A2 (pt)	2016-06-21	composto, composição farmacêutica e processo para preparar um composto
BRPI0815784A2 (pt)	2015-02-24	Processo para a preparação de 1,2-propanodiol
BRPI0612254A2 (pt)	2016-09-06	composto, formulação farmacêutica, combinação, e, processo para preparar um composto
BRPI0816331A2 (pt)	2015-04-14	Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto.
BRPI0910545A2 (pt)	2015-09-29	processo contínuo para fazer composições farmacêuticas
BRPI1011888A2 (pt)	2016-04-12	processo para preparar um composto, e, composição.
BRPI0911897A2 (pt)	2015-07-28	Processo para a preparação de compostos, e, composto
BRPI0905847A2 (pt)	2016-08-09	"composição farmacêutica injetável e processo para preparar a composição"
BRPI1007161A2 (pt)	2016-02-23	composição farmacêutica oral, e processo para preparar uma composição
BRPI0813438A2 (pt)	2014-12-23	Processo para preparar um composto, uso de um composto, e, composto.
BR112012016201A2 (pt)	2017-12-19	''composto, processo para a preparação de um composto, composição farmacêutica e uso de um composto''
BRPI0813772A2 (pt)	2014-12-30	Composto, processo para a preparação de um composto, e, conjugado
BRPI0814163A2 (pt)	2015-01-20	Processo para a preparação de compostos, forma cristalina, e, composição farmacêutica
BRPI1016109A2 (pt)	2016-05-17	"composto, composição farmacêutica, e, processo para preparar um composto"
BRPI1007654A2 (pt)	2016-02-23	composto, processo para a obtenção de um composto de fórmula geral e composição farmacêutica
BRPI0818678A2 (pt)	2015-04-14	Processo para preparar eteno
BRPI0922714A2 (pt)	2016-01-05	composto, processo para preparar um compsoto, medicamento, uso de um composto, e, composição farmacêutica

Legal Events

Date	Code	Title	Description
2015-12-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.
2016-03-29	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.